Oncodesign Precision Medicine
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more
Oncodesign Precision Medicine (ALOPM) - Total Liabilities
Latest total liabilities as of December 2023: €12.94 Million EUR
Based on the latest financial reports, Oncodesign Precision Medicine (ALOPM) has total liabilities worth €12.94 Million EUR as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncodesign Precision Medicine - Total Liabilities Trend (2020–2024)
This chart illustrates how Oncodesign Precision Medicine's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oncodesign Precision Medicine Competitors by Total Liabilities
The table below lists competitors of Oncodesign Precision Medicine ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WANT WANT CHINA
BE:4HQ
|
Germany | €11.05 Billion |
|
NB Distressed Debt Inv Extended Life
LSE:NBDX
|
UK | $2.75 Million |
|
Earth Gen-Biofuel Inc
PINK:EGBB
|
USA | $9.34 Million |
|
Tattooed Chef Inc.
PINK:TTCFQ
|
USA | $119.69 Million |
|
Rapid-Line Inc.
OTCGREY:RPDL
|
USA | $26.15K |
Liability Composition Analysis (2020–2024)
This chart breaks down Oncodesign Precision Medicine's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncodesign Precision Medicine's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncodesign Precision Medicine (2020–2024)
The table below shows the annual total liabilities of Oncodesign Precision Medicine from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €11.14 Million | -13.92% |
| 2023-12-31 | €12.94 Million | +96.43% |
| 2022-12-31 | €6.59 Million | +57.91% |
| 2021-12-31 | €4.17 Million | -23.31% |
| 2020-12-31 | €5.44 Million | -- |